Abstract
As the most common form of arthritis, osteoarthritis (OA) is prevalent in the elderly, bringing patients pain and functional limitations of joints. Current medication treatments of OA mainly consist of oral and intra-articular administration. Despite the undeniable advantages over oral administration, the efficacy of intra-articular therapy is still limited by the rapid clearance of drugs. To guarantee the efficacy and avoid frequent injections, rationally designed intra-articular drug delivery systems (DDSs), which may remain in OA joints for a long time and sustainedly release drugs, are clinically in need. In this article, we present a review of the novel intra-articular DDSs for OA treatment reported recently, especially in the last five years. Factors influencing the biocompatibility and efficacy of such systems are also addressed. Moreover, the potential fate of different systems in joints is highlighted. Future innovations in this field may lie in the discovery of effective DMOADs and the development of novel biomaterials as carriers of bioactivity substances.
Keywords: Depot formulation, drug delivery system, intra-articular administration, osteoarthritis (OA), targeted delivery.
Current Drug Targets
Title:Progress in Intra-Articular Drug Delivery Systems for Osteoarthritis
Volume: 15 Issue: 9
Author(s): Xiaoye Yang, Hongliang Du and Guangxi Zhai
Affiliation:
Keywords: Depot formulation, drug delivery system, intra-articular administration, osteoarthritis (OA), targeted delivery.
Abstract: As the most common form of arthritis, osteoarthritis (OA) is prevalent in the elderly, bringing patients pain and functional limitations of joints. Current medication treatments of OA mainly consist of oral and intra-articular administration. Despite the undeniable advantages over oral administration, the efficacy of intra-articular therapy is still limited by the rapid clearance of drugs. To guarantee the efficacy and avoid frequent injections, rationally designed intra-articular drug delivery systems (DDSs), which may remain in OA joints for a long time and sustainedly release drugs, are clinically in need. In this article, we present a review of the novel intra-articular DDSs for OA treatment reported recently, especially in the last five years. Factors influencing the biocompatibility and efficacy of such systems are also addressed. Moreover, the potential fate of different systems in joints is highlighted. Future innovations in this field may lie in the discovery of effective DMOADs and the development of novel biomaterials as carriers of bioactivity substances.
Export Options
About this article
Cite this article as:
Yang Xiaoye, Du Hongliang and Zhai Guangxi, Progress in Intra-Articular Drug Delivery Systems for Osteoarthritis, Current Drug Targets 2014; 15 (9) . https://dx.doi.org/10.2174/1389450115666140804155830
DOI https://dx.doi.org/10.2174/1389450115666140804155830 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relevance of CYP2C9 Function in Valproate Therapy
Current Neuropharmacology The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress
Current Molecular Medicine The Basement Membrane Zone in Asthma
Current Respiratory Medicine Reviews Probing Heterotrimeric G Protein Activation: Applications to Biased Ligands
Current Pharmaceutical Design Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients
Current Alzheimer Research Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential
Current Stem Cell Research & Therapy Age Matching Animal Models to Humans - Theoretical Considerations
Current Drug Discovery Technologies EGF Receptor as a Drug Target in Arterial Hypertension
Mini-Reviews in Medicinal Chemistry Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) HIV-1 Capsid Inhibitors as Antiretroviral Agents
Current HIV Research Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Purinergic Signaling and Hippocampal Long-Term Potentiation
Current Neuropharmacology Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience The Characteristic of Histopathology in Spondyloarthropathy
Current Rheumatology Reviews Recognition of Nucleic Acid Ligands by Toll-Like Receptors 7/8: Importance of Chemical Modification
Current Medicinal Chemistry Graphical Abstracts
Inflammation & Allergy - Drug Targets (Discontinued) Dopamine: The Forgotten Felon in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hydroethanolic Extract of <i>Lampaya Medicinalis</i> Phil. (<i>Verbenaceae</i>) Decreases Proinflammatory Marker Expression in Palmitic Acid-exposed Macrophages
Endocrine, Metabolic & Immune Disorders - Drug Targets